CARA - Cara Therapeutics, Inc.
| Previous Close | 15.35 |
| Open | 15.30 |
| Bid | 15.00 x 2900 |
| Ask | 15.88 x 800 |
| Day's Range | 15.09 - 15.56 |
| 52 Week Range | 11.46 - 24.30 |
| Volume | 520,671 |
| Avg. Volume | 596,633 |
| Market Cap | 605.114M |
| Beta (3Y Monthly) | 3.86 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.98 |
| Earnings Date | Aug 3, 2017 - Aug 7, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.10 |
- Investopedia•2 days ago
Top Marijuana Stocks on the NASDAQ
Although the majority of U.S.-based cannabis companies and many foreign ADRs trade over-the-counter, a few marijuana companies are traded on the NASDAQ. Some investors prefer stocks that are listed on the NASDAQ to other exchanges due to their increased liquidity and tighter spreads than the OTC markets.
- InvestorPlace•5 days ago
With Trial Results Due, This Could Be a Breakout Year for Cara Stock
Cara Therapeutics (NASDAQ: CARA) continues its study on KORSUVA (difelikefalin), used for dialysis-dependent CKD patients with pruritus. Even though the primary completion date is in March, Cara stock will probably not move until afterward, if at all. Still, an improving score on the itching intensity scale could only help the stock. But first, all eyes will be on Cara's quarterly earnings report. * 7 Retail Stocks to Buy for the Rise of Menswear ### Last Quarter's Earnings Report Recap Cara reported third-quarter results in Nov. 2018. Earnings were not in the spotlight because the company lost $19.4 million, or $0.51 per basic share. It brought in $5 million in revenue, stemming from license and milestone fees. InvestorPlace - Stock Market News, Stock Advice & Trading Tips In the quarter, Cara solidified its balance sheet in a way that is typical with emerging biotech firms: it sold shares. The public offering netted $92.1 million, with 5.175 million shares issued at $19 a share. Though the stock traded as low as around $12 during Dec. 2018's sell-off, it recovered back to $15.43. This is still well off from the share issuance price. ### Phase Three Progress The phase three study of Korsuva (CR845) across its pipeline for pruritus is the highlight of its Q3 activity. This involved enrolling subjects across 60 U.S. sites. By the end of 2018, Cara should have had 80 U.S. sites and 350 patients enrolled in both the KALM-1 and KALM-2 studies. Both trials are designed to investigate the dose efficacy of Korsuva at 0.5 micrograms per kilo compared to a placebo. This is administered three times a week, for 12 weeks. Given that shares are somewhat range-bound, markets are in wait-and-see mode with the primary efficacy endpoint results. The secondary endpoint will measure the quality of life, including itch levels. Cara Pharmaceuticals expects the trial completed within the first half of 2019. ### Cash Burn Rate and Cara Stock Knowing how much cash a biotech company is burning is useful. It may give shareholders an idea on when Cara may sell shares again and potentially pressuring its share price. In its third quarter, R&D costs rose to $22.3 million, up from $9.2 million in the same period of 2017. Clinical trial costs rose last year, as did stock compensation and staffing costs. Cara ended with $206.1 million in cash at the end of Sep 30, 2018. Without accounting for any potential milestone payments, Cara has enough cash to carry on its research work through into 2021. ### Product Commercialization Cara's products are too early in the study phase to be thinking and planning a product commercialization plan. So, the near-term catalysts for CARA stock will be the clinical results from its studies. Fortunately, management believes it faces minimal competition for CKD-related pruritus. Its drug shows effectiveness, compared to the alternative treatment options. ### Outlook for CARA Stock in 2019 Last year was loaded with clinical trial activities for Cara. The stock traded at between $11.43 and $24.30. Much of the drop is attributable to the drop in the biotech sector. This selling accelerated in Dec. 2018. Results from the studies involving pruritus are positive catalysts for the stock for 2019. If the drug is approved, Cara receives $30 million for the regulatory approval step. Commercial milestones will bring in up to $440 million. So at the $600 market cap, investors are paying only a dollar in market value for the milestone revenue received from its partner, VFMCRP. ### Risks Investing in Cara is not without risks. Any disappointing results from the studies could send CARA stock sharply lower. A general sell-off in the markets will hurt biotech stocks even more. In bearish times, markets tend to punish speculative companies that do not have a product on the market or a study stream of revenue to count on. Disclaimer: None ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Companies Apple Should Consider Buying * 7 Beaten-Up Housing Stocks Due for a Bounce Back * Take Buffett's Advice: 5 Vanguard Funds to Buy Compare Brokers The post With Trial Results Due, This Could Be a Breakout Year for Cara Stock appeared first on InvestorPlace.
- Market Realist•7 days ago
These Cannabis Stocks Are Soaring in January
These Cannabis Stocks Are Soaring in JanuaryCannabis stock trendsCannabis stock CannTrust Holdings (CNTTF) rose to $6.0 on January 15 from $4.8 at the close of market on December 31, 2018, representing a rise of ~25% in the first half of January
- Benzinga•8 days ago
Bank Of America Takes Neutral Stance On Cara Therapeutics Ahead Of Phase 3 Korsuva Results
Cara Therapeutics Inc (NASDAQ: CARA ) got some love from Wall Street on Tuesday, with one analyst projecting significant upside for the stock based the outlook for its leading drug candidate. The Analyst ...
- Market Realist•12 days ago
How Is INSYS Therapeutics Financially Positioned in January?
Cannabis Stock INSYS Therapeutics Is on the Rise in January (Continued from Prior Part) ## Revenue trends In the first nine months of 2018, INSYS Therapeutics’ net revenues declined ~40% YoY to reach $109.2 million from $65.7 million. In the third quarter, the company’s revenues declined ~40% YoY to reach $18.3 million from $30.7 million. Wall Street analysts estimate that INSYS Therapeutics is expected to generate revenues of $17.95 million in the fourth quarter of fiscal 2018, which represents a ~42.99% YoY decline. Analysts also estimate that INSYS Therapeutics will report net revenues of $83.74 million for fiscal 2018, which represents a ~40.48% YoY decline. Analysts estimate that GW Pharmaceuticals (GWPH) and Cara Therapeutics (CARA), INSYS Therapeutics’ peers in the cannabinoid drugs market, will report net revenues of $8.7 million and $10.9 million, respectively. GW Pharmaceuticals is expected to deliver ~13.52% YoY revenue growth in fiscal 2018. INSYS Therapeutics and Lunatus signed a licensing agreement for the commercialization of Subsys in the Middle East market. The agreement could boost INSYS Therapeutics’ global footprint and business growth. ## Expenditure trends In the first nine months of 2018, INSYS Therapeutics’ cost of revenue amounted to $8.2 million compared to $16.0 million in the same period the prior year. Wall Street analysts anticipate INSYS Therapeutics’ cost of revenue to be around $9.7 million in fiscal 2018. In the first nine months of 2018, INSYS Therapeutics’ net expenses in sales and marketing (or S&M) amounted to $25.5 million compared to $41.7 million in the same period the prior year. INSYS Therapeutics reported R&D (research & development) and G&A (general & administrative) expenses of $43.2 million and $29.3 million, respectively, compared to $46.6 million and $31.8 million in the same period the prior year. Wall Street analysts estimate that the company’s S&M, G&A, and R&D expenditure will be around $32.49 million, $89.50 million, and $58.78 million, respectively, in fiscal 2018. Continue to Next Part Browse this series on Market Realist: * Part 1 - Cannabis Stock INSYS Therapeutics Has Risen 28% in January * Part 3 - How INSYS Therapeutics’ Earnings Were Trending
- Motley Fool•12 days ago
Here's Why Cara Therapeutics Fell 28.5% in December
The abuse-proof-opioid developer was swept downstream with the rest of its peers.
- Market Realist•13 days ago
A Look into GW Pharmaceuticals’ Revenue Trends
Cannabis Stock GW Pharmaceuticals Growing Steadily in January (Continued from Prior Part) ## Revenue trends In the fourth quarter of fiscal 2018, GW Pharmaceuticals (GWPH) generated revenues of $2.42 million compared to $2.45 million in the same period the prior year, reflecting ~1% YoY growth. In fiscal 2018, GW Pharmaceuticals’ net revenues grew ~15.75% YoY to reach $12.74 from $11.00. In the fourth quarter of 2018, GW Pharmaceuticals generated revenues of $10.5 million from product sales compared to $8.0 million in the same period the prior year, reflecting ~32% YoY growth. Wall Street analysts estimate that GW Pharmaceuticals will generate revenues of $8.8 million in the first quarter of fiscal 2019, which represents ~15.75% YoY growth. Analysts also estimate that GW Pharmaceuticals’ net revenues in fiscal 2019 will be around $122.66 million. GW Pharmaceuticals is strengthening its supply chain of Epidiolex. GW Pharmaceuticals’ regulatory filing for approval of Epidiolex in the European market is under review by the European Medicines Agency (or EMA). The company anticipates the EMA’s decision by the first quarter of fiscal 2019. The approval of the drug in the European market could significantly boost the revenue growth of GW Pharmaceuticals. ## Peers’ performance Cara Therapeutics (CARA) and Insys Therapeutics (INSY), GW Pharmaceuticals’ peers in the medical cannabis market, reported revenues of $5.0 million and $18.35 million, respectively, in the third quarter of fiscal 2018. Wall Street analysts estimate that Cara Therapeutics and Insys Therapeutics will report net revenues of $10.9 million and $83.74 million, respectively, in fiscal 2018. The revenue growth of GW Pharmaceuticals, Cara Therapeutics, and Insys Therapeutics could boost the ETFMG Alternative Harvest ETF (MJ). GW Pharmaceuticals, Cara Therapeutics, and Insys Therapeutics make up ~5.95%, ~1.52%, and ~1.64% of MJ’s total portfolio holding. In the next article, we’ll discuss GW Pharmaceuticals’ other earnings and operational expenditure trends. Continue to Next Part Browse this series on Market Realist: * Part 1 - GW Pharmaceuticals Has Already Soared 23% in January * Part 3 - How GW Pharmaceuticals’ Earnings Are Trending * Part 4 - Here Are Some of GW Pharmaceuticals’ Key Growth Drivers
- GlobeNewswire•16 days ago
Cara Therapeutics Completes Enrollment of KALM-1 Pivotal Phase 3 Trial Of KORSUVA™ (CR845/ difelikefalin) Injection in Hemodialysis Patients with Pruritus
Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on the treatment of pruritus by selectively targeting peripheral kappa opioid receptors, today announced completion of enrollment in the KALM-1 Phase 3 trial of KORSUVA™ (CR845/ difelikefalin) Injection in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). More than 350 hemodialysis patients with CKD-aP have now been randomized across approximately 60 clinical sites in the United States. “Completion of enrollment in the first pivotal Phase 3 trial is an important milestone toward our goal of developing KORSUVA™ Injection as a first-in-class therapeutic for hemodialysis patients suffering from pruritus,” said Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics.
- Investor's Business Daily•19 days ago
Which Biopharma Stocks Are Looking To Score Big In Cannabis Medicine?
Now that one cannabis-based drug has won FDA approval, a wide range of drugmakers, from small biotech stocks to giant pharma firms, are exploring the substance to treat a host of maladies.
- Zacks•19 days ago
Cara (CARA) Up on IDMC's Recommendation to Continue Trial
Cara (CARA) gains after IDMC recommended the late-stage trial on lead drug, Korsuva, to continue without any modifications.
- GlobeNewswire•21 days ago
Cara Therapeutics Announces No Modifications in Trial Size After Completion of Interim Statistical Assessment For KALM-1 Phase 3 Trial Of KORSUVA™ Injection in Hemodialysis Patients with Pruritus
Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on the treatment of pruritus by selectively targeting peripheral kappa opioid receptors, today announced the completion of an interim statistical analysis of its pivotal KALM-1 Phase 3 trial of KORSUVA™ (CR845/difelikefalin) Injection in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). Based on the recommendation of the Independent Data Monitoring Committee (IDMC), the trial will continue as planned with no changes to the original enrollment target of 350 patients.
- Insider Monkey•last month
Is Casa Therapeutics Inc (CARA) Going to Burn These Hedge Funds?
Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals. They generate significant returns for investors to justify their large fees and they allocate a lot of time and employ a complex analysis to determine the best stocks to invest in. A particularly […]
Market Realist•last monthWhat’s Auxly Cannabis’ MidStream Strategy in 2018?
Auxly Cannabis (CBWTF) competes with multiple players like Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), Insys Therapeutics (INSY), Aphria (APHA), Aurora Cannabis (ACB), and Canopy Growth (CGC) in areas like pharmaceutical, health and wellness, vertical integration, and adult use in the midstream segment.
- InvestorPlace•last month
Cara Therapeutics Stock Could Outperform in 2019
When investors think of medical cannabis stocks, names like GW Pharmaceuticals (NASDAQ:GWPH) and more recently Tilray (NASDAQ:TLRY) come to mind before Cara Therapeutics (NASDAQ:CARA) does. Indeed, if someone knew nothing about CARA and examined its website, it would be difficult to determine that CARA stock is even a play on the proliferation of medical marijuana. Cara Therapeutics is involved in medical marijuana, though, and arguably has more credibility in the field than many other hot pot stocks.
- ACCESSWIRE•last month
4 Marijuana Stocks To Watch On Tuesday 12/18/2018
CORAL GABLES, FL / ACCESSWIRE / December 18, 2018 / Marijuana stocks have seen a lot of excitement this year. As 2019 gets closer, Premier Health Group (OTC: PHGRF) (CSE: PHGI) , Aurora Cannabis (NYSE: ...
- Benzinga•last month
Jim Cramer Advises His Viewers On Apache, Waste Management And More
On CNBC's "Mad Money Lightning Round" , Jim Cramer said he would just watch Apache Corporation (NYSE: APA ). It doesn't have a good enough yield for this market. Roku Inc's (NASDAQ: ROKU ) fundamentals ...
- CNBC•last month
Cramer's lightning round: 'Yield will protect you in this awful market'
It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed. Diamondback Energy Inc. FANG : "No. I gave a club call today for ActionAlertsPlus.com and … what I said was you can't own the regular E&Ps right here, the exploration and production. Can you imagine if Amazon's really a Trojan horse and that Alexa's going to start showing advertisements?
- ACCESSWIRE•last month
A Solution to the Nation's Current Opioid Overdose Epidemic and The World's Leading Cause of Disability
HENDERSON, NV / ACCESSWIRE / December 17, 2018 / Low back pain is the leading cause of disability in the world and the second most cause of disability in the United States. Degenerative disc disease is one of the most common causes of back pain, affecting more than 3 million people in the US per year. Is estimated that the cost for back pain range from to "at least $50 billion per year" (American Chiropractic Association) to $86 billion per year (WebMD) and to more than $200 billion dollars per year (American Academy of Orthopaedic Surgeons).
- ACCESSWIRE•last month
This Unknown Stock With A Market Opportunity Rivaling Cannabis Could Offer Big Upside For Investors
Medical marijuana and its derivatives are gaining rapid acceptance in the U.S. and Canada, and you can see the trend reflected in recent public market action from companies in this space, like Cara Therapeutics (CARA) and CV Sciences Inc. (CVSI) for example. Neurostimulation is also transforming numerous neurological conditions, just like medical marijuana.
- ACCESSWIRE•last month
CBD Industry Growth Sparks Momentum For Marijuana Stocks
CORAL GABLES, FL / ACCESSWIRE / December 11, 2018 / The Brightfield Group, a research firm, recently published a 2018 market overview and analysis on hemp-derived CBD . The summary of their analysis states, ...
- ACCESSWIRE•last month
Alternatives to Watch
HENDERSON, NV / ACCESSWIRE / December 10, 2018 / Below are several companies positioning themselves to be a viable opioid alternative. We are highlighting: Endonovo Therapeutics, Inc. (ENDV), INSYS Therapeutics, ...
- InvestorPlace•2 months ago
The Trade War Could Be a Positive Catalyst for Cara Therapeutics Stock
For all the hype and media attention around the G20 summit in Argentina, it’s clear that U.S.-Chinese trade relations won’t be fixed overnight. One of the topics they have to discuss, interestingly enough, appears to be America’s opioid crisis. As a result, America’s opioid crisis will become more prominent in news coverage, potentially providing a positive catalyst for Cara Therapeutics (NASDAQ:CARA) and CARA stock.
- Motley Fool•2 months ago
Why Cara Therapeutics Is Up 50% in 2018
Three key reasons behind this clinical-stage biotech's impressive year-to-date performance.
- ACCESSWIRE•2 months ago
Opioid Alternatives Could Make Investors Major Gains
HENDERSON, NV / ACCESSWIRE / November 21, 2018 / Moderna and Synthorx's huge IPOs show biotech point to a strong biotech sector that should continue a bull run heading into the new year. CBD based biotechs ...
- Market Realist•2 months ago
MedMen’s Territory Expansion: The Recent Agreements
MedMen (MMNFF) has entered into agreements with different companies to expand its footprint. We outline a few of the recent agreements below.
